HPV vaccination is also effective hpv virus cause bleeding males to protect their partners from HPV infections, as well as themselves from anal cancer and genital warts, and possibly other HPV associated cancers.
Two vaccines have market approval in many countries as of called Gardasil and Cervarix in the US. Both vaccines have been shown to prevent precancerous lesions of the cervix.
Worldwide, HPV is the most common sexually transmitted infection in adults. CIN is a precursor to cervical cancer, and is painful and costly to treat.
Human papillomavirus infection discharge is not known how many women worldwide are diagnosed with CIN. Since the vaccine only covers some high-risk types of HPV, experts still recommend that women get Pap smear screenings even after vaccination.
Gardasil and Cervarix are preventive vaccines and do not treat HPV infection or cervical cancer. Both Gardasil and Cervarix have been shown to prevent cervical dysplasia from the high-risk HPV types 16 and 18 and some protection against a few closely related high-risk HPV types.
However, there are other high-risk HPV types that are not affected by the vaccines. The protection against HPV 16 and 18 has lasted at least 8 years after vaccination for Gardasil and more than 9 years for Cervarix.
It is thought that booster vaccines will not be necessary. Immunization with Cervarix consists of 3 doses of 0. The preferred site of administration is the deltoid region of the upper arm.
In the United States, Cervarix is approved for use in females 10 through 25 years of age while in some other countries the age limit is at least